search button
Open Access

Impact of timing of radium‑223 administration on the survival of patients with bone metastatic castration‑resistant prostate cancer

  • Authors:
    • Kenji Makita
    • Yasushi Hamamoto
    • Hiromitsu Kanzaki
    • Natsumi Yamashita
    • Kei Nagasaki
    • Teruhito Kido
    • Noriyoshi Miura
    • Takashi Saika
    • Katsuyoshi Hashine

  • View Affiliations

  • Published online on: July 11, 2023     https://doi.org/10.3892/mi.2023.98
  • Article Number: 38

  • Copyright : © Makita et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The present study aimed to evaluate the optimal timing of radium‑223 chloride (Ra‑223) administration among patients with bone metastasis from castration‑resistant prostate cancer (BmCRPC). Patients, who were diagnosed with BmCRPC and treated with Ra‑223 therapy between October, 2016 and January, 2022, were reviewed. The survival time was calculated from the initiation of Ra‑223 administration. The time from the diagnosis of BmCRPC to the initiation of Ra‑223 administration was identified as a potential prognostic factor. A total of 51 patients were examined in the present study. Ra‑223 was administered as the first‑ and second‑line therapy (earlier Ra‑223 administration) in 32 patients and as the third‑ to fifth‑line therapy (later Ra‑223 administration) in 19 patients. In the multivariate analysis, which considered the potential prognosis, the difference in survival times between patients who received early and late Ra‑223 administration was not significant [hazard ratio (HR), 2.67; 95% confidence interval (CI), 0.79‑9.07; P=0.11]. By contrast, an incomplete Ra‑223 administration (HR, 128.03; 95% CI, 10.59‑1548.42; P<0.01) and higher levels of prostate‑specific antigen prior to Ra‑223 administration (HR, 7.86; 95% CI, 2.7‑27.24; P<0.01) were independent factors, significantly associated with a poorer prognosis. The timing of Ra‑223 administration did not significantly affect the survival of patients from the initiation of treatment. Further studies are thus required to determine the optimal timing for Ra‑223 administration.
View Figures
View References

Related Articles

Journal Cover

July-August 2023
Volume 3 Issue 4

Print ISSN: 2754-3242
Online ISSN:2754-1304

Sign up for eToc alerts

Recommend to Library

International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Makita K, Hamamoto Y, Kanzaki H, Yamashita N, Nagasaki K, Kido T, Miura N, Saika T and Hashine K: Impact of timing of radium‑223 administration on the survival of patients with bone metastatic castration‑resistant prostate cancer. Med Int 3: 38, 2023.
APA
Makita, K., Hamamoto, Y., Kanzaki, H., Yamashita, N., Nagasaki, K., Kido, T. ... Hashine, K. (2023). Impact of timing of radium‑223 administration on the survival of patients with bone metastatic castration‑resistant prostate cancer. Medicine International, 3, 38. https://doi.org/10.3892/mi.2023.98
MLA
Makita, K., Hamamoto, Y., Kanzaki, H., Yamashita, N., Nagasaki, K., Kido, T., Miura, N., Saika, T., Hashine, K."Impact of timing of radium‑223 administration on the survival of patients with bone metastatic castration‑resistant prostate cancer". Medicine International 3.4 (2023): 38.
Chicago
Makita, K., Hamamoto, Y., Kanzaki, H., Yamashita, N., Nagasaki, K., Kido, T., Miura, N., Saika, T., Hashine, K."Impact of timing of radium‑223 administration on the survival of patients with bone metastatic castration‑resistant prostate cancer". Medicine International 3, no. 4 (2023): 38. https://doi.org/10.3892/mi.2023.98